Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 21:15:1508780.
doi: 10.3389/fimmu.2024.1508780. eCollection 2024.

Piloting an automated query and scoring system to facilitate APDS patient identification from health systems

Affiliations

Piloting an automated query and scoring system to facilitate APDS patient identification from health systems

Amy M FitzPatrick et al. Front Immunol. .

Abstract

Introduction: Patients with activated PI3Kδ syndrome (APDS) may elude diagnoses for nearly a decade. Methods to hasten the identification of these patients, and other patients with inborn errors of immunity (IEIs), are needed. We sought to demonstrate that querying electronic health record (EHR) systems by aggregating disparate signs into a risk score can identify these patients.

Methods: We developed a structured query language (SQL) script using literature-validated APDS-associated clinical concepts mapped to ICD-10-CM codes. We ran the query across EHRs from 7 large, US-based medical centers encompassing approximately 17 million patients. The query calculated an "APDS Score," which stratified risk for APDS for all individuals in these systems. Scores for all known patients with APDS (n=46) were compared.

Results: The query identified all but one known patient with APDS (98%; 45/46) as well as patients with other complex disease. Median score for all patients with APDS was 9 (IQR = 5.75; range 1-25). Sensitivity analysis suggested an optimal cutoff score of 7 (sensitivity = 0.70).

Conclusion: Disease-specific queries are a relatively simple method to foster patient identification across the rare-disease spectrum. Such methods are even more important for disorders such as APDS where an approved, pathway-specific treatment is available in the US.

Keywords: AI; APDS; EHR query; IEI diagnosis; diagnostic delay; inborn errors of immunity.

PubMed Disclaimer

Conflict of interest statement

AR is an employee of Pharming Healthcare, Inc. NR and CC-R serve as advisory board and steering committee members and as consultants for Pharming Healthcare, Inc. JW serves as speaker for Pharming Healthcare, Inc. NH serves as speaker and consultant for Pharming Healthcare, Inc. MB serves as a steering committee member for Pharming Healthcare, Inc. KS serves as consultant for Pharming Healthcare, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Sensitivity analysis for scores from all known patients with APDS. Balancing sensitivity with number of records captured, the arrow denotes an optimal cutoff score (7) and corresponding sensitivity of 0.70 calibrated from the centers evaluated here. Optimal threshold suggests a sensitivity of 100% and a score of 1, above which a very large number of subjects would be found effectively nullifying the need for our query.

References

    1. Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J Allergy Clin Immunol. (2019) 143:1676–87. doi: 10.1016/j.jaci.2019.03.017 - DOI - PubMed
    1. Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C. Clinical manifestations and outcomes of activated phosphoinositide 3-kinase δ syndrome from the USIDNET Cohort. J Allergy Clin Immunol Pract. (2021) 9:4095–102. doi: 10.1016/j.jaip.2021.07.044 - DOI - PMC - PubMed
    1. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. (2022) 42:1473–507. doi: 10.1007/s10875-022-01289-3 - DOI - PMC - PubMed
    1. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. J Allergy Clin Immunol. (2017) 139:597–606.e594. doi: 10.1016/j.jaci.2016.06.021 - DOI - PMC - PubMed
    1. Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Rev Immunol. (2016) 16:702–14. doi: 10.1038/nri.2016.93 - DOI - PMC - PubMed

MeSH terms

Substances